Cagrilintide (10 mg Vial) Dosage Protocol

Supplies Needed

Supply estimates below match the displayed 26-week, once-weekly 4.5 mg target-arm calculation.

• Peptide vials (Cagrilintide, 10 mg each):
  • 26 weeks: 10 vials (98.4 mg calculated total)
• Syringes:
  • Weeks 1–6: 6 U-100 insulin syringes
  • Weeks 7–26: 20 syringes able to hold 1.35 mL
  • Total: 26 single-use syringes
• Bacteriostatic water (10 mL bottles):
  • Use 3.0 mL per vial.
  • 10 vials: 30 mL → 3 bottles
• Alcohol swabs:
  • Two per administration.
  • 26 weeks: 52 swabs — 1 box required (100 swabs each)

Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.

Important Notes

Practical considerations for consistency and tolerability.

• Use new sterile syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
• Gradual dose escalation minimizes gastrointestinal side effects such as nausea^[4][6].
• Document weekly dose, injection site, and any adverse effects to maintain consistency.
• For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).

How This Works

Cagrilintide is an acylated, long‑acting analogue of amylin, a hormone co‑secreted with insulin from pancreatic beta cells^[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion^[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake^[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing^[6][11].

Potential Benefits & Side Effects

Observations from phase 2 and phase 3 clinical trials.

• Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo^[4].
• Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone^[5][12].
• Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)^[4].
• Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient^[4][5]. Gradual titration helps minimize these effects.
• Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for optimal outcomes.

• Pair with a balanced, protein‑forward diet tailored to individual energy needs.
• Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
• Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
• Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources^[13][14].

• Clean the vial stopper and skin with alcohol; allow to air dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[13].
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
• Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy^[14].

Cagrilintide 10 mg Dosage Calculations

A 10 mg vial prepared to a 3.0 mL final volume contains approximately 3.33 mg/mL. On a U-100 syringe, each unit represents 0.01 mL, so one unit contains about 0.0333 mg, or 33.3 mcg, of cagrilintide. The cagrilintide dosage chart keeps milligrams, milliliters, and U-100 markings together so the arithmetic can be checked without applying a separate conversion table.

• 0.6 mg: 0.6 mg ÷ 3.33 mg/mL = 0.18 mL = 18 U-100 units.
• 1.2 mg: 1.2 mg ÷ 3.33 mg/mL = 0.36 mL = 36 U-100 units.
• 2.4 mg: 2.4 mg ÷ 3.33 mg/mL = 0.72 mL = 72 U-100 units.
• 4.5 mg: 4.5 mg ÷ 3.33 mg/mL = 1.35 mL = 135 U-100 units.

The displayed U-100 units are volume markings rather than peptide IU. Changing the final volume changes every syringe marking, even when the peptide amount remains the same. The 4.5 mg calculation also exceeds the capacity of a standard 1 mL U-100 syringe, which is why the chart calls for a device that can accurately hold 1.35 mL.

What the 10 mg Vial Changes

The vial contains 10 mg total, but that mass is not a weekly dose. Vial strength affects concentration, injection volume, vial yield, and supply planning. It does not select a target dose or alter the phase 2 schedule shown above. At the displayed 3.0 mL final volume, the first three research amounts fit within a 1 mL syringe, while the 4.5 mg amount requires 1.35 mL.

Across the displayed 26-week calculation, the unchanged target-arm schedule uses 98.4 mg in total. Dividing that amount by 10 mg per vial produces 9.84 theoretical vials, so supply planning rounds up to 10 vials. The same principle applies to bacteriostatic water and syringes: quantities follow the number of prepared vials and administrations, while product-specific discard instructions may affect actual acquisition.

Cagrilintide Dosage Research and Trial Context

The placebo-controlled and active-controlled phase 2 dose-finding trial enrolled adults with overweight or obesity and evaluated once-weekly cagrilintide target doses from 0.3 mg to 4.5 mg over 26 weeks. Higher target-dose groups used gradual escalation rather than beginning at the final amount.^[1][4] The chart on this page isolates the published 4.5 mg target arm and translates that arm into the concentration produced by a 10 mg vial.

In that trial, reductions in body weight followed a dose-response pattern. The published estimate for the 4.5 mg group was approximately 10.8% at week 26, compared with approximately 3.0% for placebo.^[4] Those figures are group-level findings from a controlled clinical trial. They do not predict individual weight loss, establish an approved clinical dosage, or show that a larger vial should produce a larger weekly amount.

Cagrilintide is a long-acting amylin analogue designed to extend exposure compared with native amylin.^[7] Amylin signaling is associated with satiation, delayed gastric emptying, and post-meal glucagon regulation through central and peripheral pathways.^{[2][3][8][9][10]} Pharmacokinetic research supports prolonged exposure and once-weekly study designs, but interpretation still depends on the tested formulation, population, and protocol.^[6][11]

Cagrilintide Alone and Combination Research

Single-agent cagrilintide research and combination programs answer different questions. Early co-administration studies evaluated cagrilintide with semaglutide, and later REDEFINE trials studied the fixed combination commonly called CagriSema in adults with overweight or obesity and in a separate population with type 2 diabetes.^[5][6][12]

Combination outcomes cannot be assigned to cagrilintide alone. Likewise, searches for cagrilintide dosage with tirzepatide or retatrutide describe a different research question from this single-peptide page. A combination requires its own component amounts, concentration, interaction context, and evidence review. This 10 mg protocol therefore keeps the single-agent vial calculation separate from the linked Cagrilintide + Semaglutide blend protocol.

Safety, Tolerability, and Evidence Limits

Gastrointestinal events were the most common adverse effects reported in cagrilintide trials, including nausea, constipation, diarrhea, and vomiting. Frequency varied by study dose, and events were generally described as mild to moderate in the phase 2 program.^[1][4] A study summary cannot determine individual risk, and the displayed escalation remains a research reference rather than personalized guidance.

• Cagrilintide remains investigational and does not have a routine approved clinical dosage.
• Trial findings apply to defined populations, eligibility criteria, monitoring, formulations, and study durations.
• Group-level changes in body weight do not establish an individual response or long-term outcome.
• Combination-study findings must remain separate from single-agent cagrilintide findings.
• Vial strength and reconstitution volume change measurement math, not the evidence supporting a research amount.

Cagrilintide Dosing Protocol and Research Terminology

Cagrilintide is an amylin analogue and an investigational research peptide developed by Novo Nordisk. Unlike GLP-1 receptor agonists like semaglutide, cagrilintide mimics amylin signaling. In research models, cagrilintide slows gastric emptying, supports satiation pathways, and alters post-meal glucagon signaling.^{[2][3][7][10]}

The cagrilintide dosing protocol above retains the published once-weekly dosing and two-week titration schedule. This dosing schedule distinguishes vial concentration from target dose and is not an approved or recommended dosage. The phase 2 program also studied a 2.4 mg dose; references to 2.4 mg weekly and 4.5 mg per week describe research target groups rather than strength-specific instructions.^[1][4]

The effects of cagrilintide were also evaluated in combination with semaglutide. REDEFINE research compared the fixed combination with semaglutide alone and cagrilintide alone, while a separate trial enrolled adults with type 2 diabetes and assessed weight loss and glycemic outcomes. Combination dosing, including cagrilintide 2.4 mg with semaglutide 2.4 mg, belongs to that separate evidence context and does not change the single-agent calculation on this page.^[5][6][12]

This strength-specific dosing guide keeps cagrilintide reconstitution math, syringe markings, and vial yield explicit. A cagrilintide dosage calculator can only return correct volume markings when the vial mass and final liquid volume are entered together.

Cagrilintide 10 mg Dosage Questions

Does a 10 mg vial mean the dose is 10 mg?

No. Ten milligrams is the total peptide mass in the vial. The amount per administration, concentration, injection volume, syringe markings, and frequency must be interpreted together.

How many U-100 units equal 0.6 mg at this concentration?

With a 3.0 mL final volume, the concentration is approximately 3.33 mg/mL. A 0.6 mg amount equals 0.18 mL, or 18 U-100 units. A different final volume produces different markings.

How many U-100 units equal 4.5 mg?

At approximately 3.33 mg/mL, 4.5 mg equals 1.35 mL, or 135 U-100 units. That volume is larger than a standard 1 mL U-100 syringe can hold, so an appropriately sized and accurately graduated device is required for the displayed calculation.

Why does the chart use a 26-week period?

The 26-week period and two-week escalation phases come from the published phase 2 target arm summarized on this page.^[1][4] The period is part of the study description, not a universal recommendation.

Is cagrilintide the same as CagriSema?

No. Cagrilintide is the amylin analogue. CagriSema combines cagrilintide with semaglutide and has separate combination-trial evidence.^[5][12]